髋部骨折患者体位摆放时不同股神经阻滞方法镇静、镇痛效果探讨

Analgesic and sedative effects of different femoral nerve blocks of patients with hip fracture at operative position

  • 摘要: 目的 比较右美托咪定、0.375%罗哌卡因以及2者联用在髋部骨折患者股神经阻滞体位摆放时的镇痛、镇静效果。 方法 选择髋部骨折拟行内固定术患者150例,随机分为3组各50例。A组给予0.375%罗哌卡因股神经阻滞, B组给予静脉注射0.2 μg/kg右美托咪定, C组给予静脉注射0.2 μg/kg右美托咪定联合0.375%罗哌卡因股神经阻滞。比较3组患者入室时(T0)、摆放体位前(T1)、摆放体位时(T2)、椎管内麻醉结束(T3)时平均动脉压(MAP)、心率(HR)、脉搏血氧饱和度(SpO2), 比较3组患者摆放体位时的镇痛[采用视觉模拟评分法(VAS)评估]、镇静[采用改良警觉/镇静评分(OAA/S)评估]效果,记录3组患者的不良反应发生情况。 结果 A组、C组T1、T2、T3时MAP、HR水平显著低于同组T0时的水平(P<0.05), B组T1、T3时MAP、HR水平显著低于T0时(P<0.05), 且B组T2时MAP显著高于A组、C组(P<0.05)。B组、C组T3时HR显著低于A组(P<0.05)。C组T1、T2时HR显著低于A组、B组(P<0.05)。A组、C组T2时VAS评分显著低于同组T0 时及B组T2时(P<0.05), 但A组与C组比较无显著差异(P>0.05)。B组、C组T1时OAA/S评分显著高于同组T0时及B组T1时(P<0.05), 但B组与C组比较无显著差异(P>0.05)。A组无患者发生不良反应, B组1例(2.00%)恶心、呕吐, C组1例(2.00%)眩晕。3组不良反应发生率比较无显著差异(P>0.05)。 结论 右美托咪定联合0.375%罗哌卡因在髋部骨折椎管内麻醉体位摆放时的镇静、镇痛效果确切,对患者血流动力学影响较小,且不良反应少。

     

    Abstract: Objective To compare the analgesic and sedative effects of dexmedetomidine combined with 0.375% ropivacaine and their use alone in femoral nerve block for patients with hip fracture at operative position. Methods Totally 150 hip fracture patients with internal fixation were randomly divided into three groups, with 50 cases in each group. Group A was treated with 0.375% ropivacaine for femoral nerve block, group B was treated with intravenous injection of 0.2 μg/kg dexmedetomidine, and group C was treated with 0.2 μg/kg dexmedetomidine combined with 0.375% ropivacaine for femoral nerve block. The mean arterial pressure(MAP), heart rate(HR)and pulse oxygen saturation(SpO2)were compared among the three groups at the time points of entering the room(T0), before taking position(T1), taking position(T2), and at the end of spinal anesthesia(T3). The analgesic effect [assessed by Visual Analogue Scale(VAS)] and sedative effect [assessed by modified Observer's Assessment of Alertness/Sedation(OAA/S)] were compared among the three groups. Adverse reactions of the three groups were recorded. Results Levels of MAP and HR at T1, T2 and T3 were significantly lower than those at T0 in the group A and the group C(P<0.05), levels of MAP and HR at T1 and T3 were significantly lower than those at T0 in the group B(P<0.05), and MAP at T2 in the group B was significantly higher than that in the group A and the group C(P<0.05). The - levels of HR at T3 in the group B and the group C were significantly lower than that in the group A (P<0.05). The levels of HR at T1 and T2 in the group C were significantly lower than that in the group A and the group B(P<0.05). The VAS scores at T2 in the group A and the group C were significantly lower than those at T0 in the same groups and at T2 in the group B(P<0.05), but there was no significant difference between the group A and the group C(P>0.05). The OAA/S scores at T1 in the group B and the group C were significantly higher than that at T0 in the same groups and at T1 in the group B(P<0.05), but there were no significant differences between the group B and the group C(P>0.05). No adverse reactions were observed in the group A, but there were 1 case(2.00%)with nausea and vomiting in the group B and 1 case(2.00%)with vertigo in the group C. There was no significant difference in the incidence of adverse reactions among the three groups(P>0.05). Conclusion Dexmedetomidine combined with 0.375% ropivacaine has exact sedative and analgesic effects at taking position in hip fracture patients with intraspinal anesthesia, which has less influence on hemodynamics and fewer adverse reactions.

     

/

返回文章
返回